Milestone Reached in Registrational Trial for LCA5-Associated Inherited Retinal Disease
Opus Genetics has announced the completion of patient enrollment in its registrational Phase 3 clinical trial evaluating OPGx-LCA5, an investigational gene therapy for LCA5-associated inherited retinal disease (IRD). This milestone marks a significant step forward for patients and families affected by this rare and severe form of early-onset childhood blindness.
Key Trial Details and Regulatory Progress
According to Opus Genetics, the Phase 3 trial is evaluating the safety and efficacy of a one-time subretinal administration of OPGx-LCA5 in patients with genetically confirmed disease. Key elements of the trial include:
- Trial Design: The study incorporates a six-month run-in period where participants serve as their own natural history control before receiving treatment.
- Regulatory Alignment: The study was designed in collaboration with the U.S. Food and Drug Administration (FDA) to support a potential Biologics License Application (BLA).
- Designations: OPGx-LCA5 has previously earned Orphan Drug, Rare Pediatric Disease, and Regenerative Medicine Advanced Therapy (RMAT) designations, and was accepted into the FDA's Rare Disease Evidence Principles (RDEP) program.
What This Means for Patients and Families
LCA5-associated IRD is caused by biallelic mutations in the LCA5 gene, leading to the disruption of lebercilin and profound vision loss early in life. Currently, there are no approved treatment options for this condition. The advancement of OPGx-LCA5 offers renewed hope for a community with high unmet medical needs, aiming to deliver a durable, one-implant genetic therapy directly to the photoreceptors.
Looking Ahead
With enrollment officially complete, participants are currently finishing their run-in periods. Opus Genetics reports that it remains on track to initiate patient dosing in the fourth quarter of 2026 and anticipates reporting topline six-month efficacy data by the end of 2027.